Previous Article | Next Article ![]()
Infect Immun, June 1998, p. 2755-2761, Vol. 66, No. 6
UIMEIP,
Received 11 December 1997/Returned for modification 2 February
1998/Accepted 11 March 1998
Toxins A and B from Clostridium difficile are the main
cause of antibiotic-associated diarrhea and pseudomembranous colitis. They cause fluid accumulation, necrosis, and a strong inflammatory response when inoculated in intestinal loops. Since mast cells are a
rich source of inflammatory mediators, abundant in the gut, and known
to be involved in C. difficile-induced enteritis, we studied the in vitro effect of toxin A on isolated mast cells. Normal
rats sensitized by infection with Nippostrongilus
brasiliensis were used to isolate peritoneal mast cells (PMC).
PMC from naive rats were stimulated with calcium ionophore A23187 as a
model of antigen-independent activation, and PMC from sensitized rats were stimulated with N. brasiliensis antigens to study
immunoglobulin E-dependent mast cell activation. After 4 h, toxin
A did not induce release of nitric oxide or histamine in naive PMC.
However, 10 ng of toxin per ml caused a significant release of tumor
necrosis factor alpha (TNF- Clostridium difficile is
the etiologic agent of antibiotic-associated diarrhea and
pseudomembranous colitis (1). Antibiotics and cytotoxic
drugs disturb colonic flora, allowing overgrowth of C. difficile and production of toxins A and B. Toxin A elicits an
acute inflammatory response, congestion, and necrosis when inoculated
in the gut (1, 14, 36, 44). It is chemotactic and induces
the release of inflammatory mediators by macrophages and neutrophils
(9, 24, 31). Some studies suggested that mast cells also
play an important role in the pathophysiology of toxin A
(25). Thus, toxin A administered into ileal loops of rats
elicited the release of inflammatory mediators such as leukotriene B4,
platelet-activating factor, and rat mucosal mast cell protease II
(RMCPII) (6, 26, 35). Moreover, treatment of animals with
the antiallergy and antiinflammatory agent ketotifen, with the H1
histamine antagonist iodoxamide, or with histaminase reduced the
inflammation and secretory responses caused by toxin A (12, 25,
34). It has been proposed that toxin A induces the secretion of
inflammatory mediators from mast cells either directly, or indirectly
through the release of substance P, a known activator of mucosal mast
cells (7, 19, 29).
Mast cells are widely distributed in the intestinal mucosa, in skin and
around blood and lymphatic vessels, and in many other tissues and
organs. They can be activated to release inflammatory mediators via
immunoglobulin E (IgE)-dependent and IgE-independent mechanisms
(16). In IgE-independent mechanisms, mast cells can be
activated by substances such as calcium ionophore, compound 48/80,
substance P, and microbial products (11, 16). They can
release potent mediators of inflammation and recently have been shown
to play a pivotal role in host defense against bacterial infection
(11, 28). The defenses in sepsis are dependent on mast cells
that produce tumor necrosis factor alpha (TNF- Thus, to investigate whether toxin A has direct effects on mast cells,
we analyzed the influence of toxin A on the secretion of histamine,
TNF- Rat PMC.
Peritoneal mast cells (PMC) were from 250- to 300-g
male Sprague-Dawley rats (Charles River, Canada Inc.), maintained under standard laboratory conditions with food and water ad libitum. PMC were
obtained by lavage of the peritoneal cavity with HEPES-buffered Tyrode's solution (HTBS) containing 0.1% bovine serum albumin and
isolated in a discontinuous gradient of sterile Percoll (Pharmacia Ltd., Uppsala, Sweden). Purity of isolated cells was checked by staining with toluidine blue (3) and observed under light
microscopy. Mast cells used in all experiments were 97 to 99% pure,
with viability of >96%. To study the IgE-dependent activation of mast
cells, rats were infected with 3,000 third-stage larvae of
Nippostrongylus brasiliensis 5 to 6 weeks before PMC
isolation (2). To evaluate activation by calcium ionophore
A23187 or toxin A, mast cells were obtained from naive rats. All
protocols used for mast cell isolation from animals were approved by
Animal Ethics Committees from University of Alberta (Canada), as well
from the Mexican Institute of Social Security.
Reagents.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
sulfanilamide, naphthylethylenediamine dihydrochloride, HEPES
(sodium salt), H3PO4, NaNo2,
calcium ionophore A23187 (Calon), 2-mercaptoethanol,
p-phenylenediamine, and E-toxate kit (Limulus amebocyte lysate, for detection of endotoxin) were from Sigma Chemical
Co. (St. Louis, Mo. C. difficile toxin A free of endotoxin, as tested with the E-toxate kit, was produced and purified as previously described (45). N. brasiliensis
antigen (NbAg) was obtained according to the procedure of White and
Pearce (47). RPMI 1640 medium was from Gibco-BRL (Grand
Island, N.Y.). Fetal bovine serum was purchased from HyClone (Logan,
Utah). Monoclonal antibodies to actin were produced and purified as
described by Diaz-Barriga et al. (10). Polyclonal antibodies
to toxin A were produced by immunization of rabbits with purified toxin
A as described previously (46).
TNF- NO production.
PMC from uninfected rats (105
cells/well) were incubated for 4 h with different concentrations
of toxin A (0.001, 0.01, 0.1, and 1 µg/ml) in RPMI 1640 without
phenol red. After washing, they were further incubated for 72 h at
37°C. Cell supernatants were mixed with an equal volume of Griess
reagent [1% sulfanilamide, 0.1%
N-(1-naphthyl)ethylenediamine dihydrochloride, 2.5%
H3PO4] and incubated for 10 min at room
temperature (20). Concentration of
NO2 Histamine release assay.
PMC (2.5 × 104)
from N. brasiliensis-infected rats were suspended in 100 µl of HBTS containing 0.1% bovine serum albumin and incubated in the
presence or absence of toxin A (0.001, 0.01, 0.1, and 1 µg/ml) for 30 min or 4 h at 37°C in a 5% CO2 atmosphere. After
incubation, cells were washed and resuspended in HBTS and challenged
with 10 worm equivalents of NbAg per ml for 20 min. Isolated PMC from
uninfected rats were also treated with toxin A, A23187 (2.5 µM), or
medium alone under the same conditions. The supernatant and cell
pellets were then separated by centrifugation at 3,000 × g.
Histamine levels were measured in both supernatant and pellet fractions
with a fluorometric assay (43) using a CytoFluor 2350 fluorescence spectrometer (Millipore Co., Bedford, Mass.). The
percentage release of the total histamine content was calculated as
described previously (4), and the spontaneous release in the
absence of toxin, A23187, or NbAg was subtracted to estimate specific
histamine release.
Cell morphology studies.
One million naive PMC were exposed
to either 1 µg of toxin A per ml or vehicle and incubated for 4 h at 37°C in a 5% CO2 atmosphere; cells were then
washed, resuspended in RPMI 1640, and further incubated for 20 h.
Subsequently, cells were fixed in 2.5% glutaraldehyde for 1 h and
postfixed in 1% OsO2 in cacodylate buffer (0.3 M, pH 7.2).
Cells were gradually dehydrated with ethanol and finally embedded in
Epon (18). The samples were thin sectioned and observed by
transmission electron microscopy (TEM) with a JEOL-X100 SX microscope
(JEOL Co., Tokyo, Japan). For scanning electron microscopy (SEM), after
dehydration the samples were critical point dried with CO2
and gold coated in an ion-sputtering device. Specimens were observed
with a JEOL 35C scanning electron microscope.
Cytoskeleton analysis.
A total of 2.5 × 104 naive PMC were incubated 37°C for 4 h with 1 µg of toxin A per ml. Cells were fixed in 3.7% paraformaldehyde in
phosphate-buffered saline (PBS; pH 7.4) for 30 min at room temperature.
After washing, the cells were permeabilized with 0.1% Triton X-100 in
PBS for 10 min at room temperature. For visualization of cytoskeletal
proteins, monoclonal antibodies directed against actin or tubulin were
added to permeabilized cells and incubated for 1 h at room
temperature (10). Cells were washed with PBS and then
incubated with a fluorescein-conjugated sheep anti-mouse IgG antibody
(1:30) (Boehringer, Mannheim, Germany) for 1 h at room
temperature. Finally, after washing with PBS, coverslips were mounted
with p-phenylenediamine in Gelvatol (100 µg/ml;
Monsanto-Birchman Bend Plant, Birchman Bend, Mass.) and analyzed with
an Olympus BH-2 fluorescence microscope (Olympus Co., Tokio, Japan).
Analysis of DNA fragmentation.
A suspension of 2 × 106 naive PMC was mixed with 1 µg of toxin A per ml and
incubated for 4 h at 37°C. Cells were then washed with PBS (pH
7.4) and resuspended in lysis buffer (10 mM EDTA, 50 mM Tris-HCl [pH
8], 0.5% sodium dodecyl sulfate) with proteinase K (500 µg/ml) and
RNase A (50 µg/ml). After incubation at 50°C for 2 h, DNA was
extracted twice with an equal volume of phenol-chloroform-isoamyl alcohol (Gibco Co., Gaithersburg, Md.). DNA obtained in the aqueous fraction was precipitated overnight in 0.1 volume of sodium acetate (3 M) and 2.5 volumes of 100% ethanol at Statistical analysis.
The two-tailed paired Student's
t test was used for statistical evaluation of TNF- The viability of PMC from both N. brasiliensis-infected
and uninfected rats was not affected by exposure of up to 4 h with doses of toxin A from 0.001 to 1 µg/ml. However, exposure to 1 µg/ml for longer periods of time (24, 48, and 72 h) decreased the viability of mast cells (17, 30, and 60%, respectively), whereas exposure to 10 µg of toxin A per ml for 4 and 24 h reduced cell viability to 12 and 26%, respectively. Accordingly, for studies of
mediator secretion, toxin A doses of up to 1 µg/ml and exposure for
up to 4 h were used.
Effect of C. difficile toxin A on TNF-
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Effects of Toxin A from Clostridium
difficile on Mast Cell Activation and Survival
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
). In contrast, 1 µg of toxin per ml
inhibited antigen or A23187-induced histamine release by PMC. Toxin A
at 1 µg/ml for 4 h caused disruption of actin which aggregated
in the cytoplasm and around the nucleus. After 24 h, chromatin
condensation, cytoplasmic blebbing, and apoptotic-like vesicles were
observed; DNA fragmentation was documented also. These results suggest
that mast cells may participate in the initial inflammatory response to
C. difficile infection by releasing TNF-
upon
interaction with toxin A. However, longer exposure to toxin A affects
the release of inflammatory mediators, perhaps because of the
alteration of the cytoskeleton and induction of apoptosis. The impaired
functions and survival of mast cells by C. difficile toxin
A could hamper the capacity of these cells to counteract the infection,
thus prolonging the pathogenic effects of C. difficile
toxins.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
), which in turn
attracts and activates neutrophils to the site of infection (28). However, in all these studies, direct evidence of
C. difficile toxin A effect on mast cells has not been
described.
, and nitric oxide (NO) in vitro. We found that toxin A did not
induce the release of histamine and NO, although it induced the release
of small amounts of TNF-
. Moreover, exposure to large doses of toxin
A inhibited mast cell activation induced by IgE-dependent and
IgE-independent mechanisms and also altered the mast cell cytoskeleton
and induced cell death by apoptosis.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
bioassay.
For the TNF-
assay, 2.5 × 104 naive PMC were mixed with different concentrations of
toxin A (0.001, 0.01, 0.1, and 1 µg/ml) in RPMI 1640 supplemented
with 10% FBS (RPMI-FBS) and incubated for 4 h at 37°C under a
5% CO2 atmosphere. Unbound toxin A was removed by
centrifugation at 600 × g, and PMC were suspended in fresh
RPMI-FBS. The cell suspension was further incubated for 6 h at
37°C. The cells were then centrifuged at 900 × g, and the supernatant was tested for TNF-
cytotoxicity on WEHI 164.13 cells (13). As a control, the direct effect of toxin A (1 to 100 ng/ml) on WEHI 164.13 cells was tested and shown not to be toxic; by contrast, with 1 µg of toxin A per ml, we observed evidence of toxicity. This alteration was abolished with rabbit antiserum (1:50
dilution). Under these conditions, TNF-
-mediated toxicity was not
modified by toxin A. Antibody to toxin A did not alter the
TNF-
-mediated toxicity of mast cells, given that antibody to TNF-
fully blocked the toxicity against WEHI cells induced by supernatants
from mast cells following toxin A stimulation. Mouse recombinant
TNF-
(Genzyme Co., Cambridge, Mass.) was used as a standard. Test
samples were assayed with concentrations of TNF-
from 0.8 to 100 pg/ml. WEHI 164.13 cells were incubated in 50 µl of RPMI-FBS with 50 µM 2-mercaptoethanol for 20 h at 37°C in 5% CO2
atmosphere. Viability of cells was measured 3 h following addition
of 10 µl of MTT (5 mg/ml) per well. Isopropanol-HCl (150 µl) was
added to dissolve the purple formazan precipitates. The plate was read
on a Vmax kinetic microplate reader (Molecular Devices Co., Menlo Park,
Calif.) at 570 nm.
was determined by measuring the
absorbance at 540 nm with a Vmax kinetic microplate reader (Molecular
Devices). NaNO2 was used as a standard.
20°C. After washing with
70% ethanol, DNA pellet was resuspended in 20 µl of TE buffer (40 mM
Tris-HCl, 1 mM EDTA), and 10 µg of DNA was electrophoresed on a 1%
agarose gel and stained with SYBR green (Molecular Probes, Eugene,
Oreg.).
and NO
studies. Results were considered significantly different when
P was <0.05. For histamine release, a three-way interaction
variance analysis was used. Results were considered significantly
different when P was <0.01 with the Scheffe test.
![]()
RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
and NO
production.
To determine the effects of toxin A on TNF-
production, PMC from uninfected rats were incubated with different
concentrations of toxin A for 4 h. TNF-
in cell-free
supernatants was assessed on TNF-
-sensitive WEHI cells. Treatment of
PMC with 0.01 or 0.1 µg of toxin A per ml stimulated
(P < 0.05) release of TNF-
(Fig. 1A), from 14.4 pg/106 in
sham-treated PMC to 36.5 or 46 pg/106 cells, respectively.

View larger version (12K):
[in a new window]
FIG. 1.
(A) Effects of toxin A (Tox A) on TNF
production by
rat PMC. Cells were incubated with toxin A for 4 h, washed, and
then cultured for an additional 6 h before the supernatants were
assayed for TNF-
or NO. Results are the means ± SE for five
experiments. Shown are effects on TNF-
production (*,
P < 0.05 by comparison with cells not treated with
toxin A). (B) Effect on NO production. PMC were treated under same
conditions as above (P > 0.05 by comparison with cells
not treated with toxin A).
Effect of toxin A on histamine release from PMC stimulated by IgE- and non-IgE-dependent pathways. To investigate the effects of toxin A on IgE-dependent histamine release, PMC from N. brasiliensis-infected and uninfected rats were incubated with different concentrations of toxin (Fig. 2). Toxin A (4-h incubation, doses from 0.001 to 1 µg/ml) did not stimulate histamine secretion from normal or N. brasiliensis-sensitized mast cells above the level of spontaneous release (2.6% ± 0.5%, mean ± standard error [SE]). However, exposure to 1 µg of toxin A per ml significantly inhibited histamine release (77%, P < 0.01) from sensitized mast cells stimulated with NbAg. To analyze the inhibitory effect of toxin A on IgE-independent histamine release, naive PMC were incubated with toxin A and then treated with A23187 (2.5 µM) for 20 min. A significant inhibition of histamine release (41%, P < 0.01) was observed when PMC were treated with 1 µg of toxin A per ml for 4 h. However, treatment of PMC with up to 1 µg of toxin A per ml for 30 min did not inhibit IgE-dependent or IgE-independent histamine release (data not shown).
|
Cytoskeletal changes associated with toxin A treatment on PMC. There were cytoskeletal changes in rat PMC after incubation with 1 µg of toxin A per ml for 4 h (Fig. 3). Sham-treated PMC cultured for 4 h showed a normal distribution of actin filaments (Fig. 3A). In contrast, PMC treated with 1 µg of toxin A per ml for 4 h showed cytoplasm retraction and cytoskeletal rearrangements with actin-containing dense deposits in the cytoplasm (Fig. 3B).
|
Morphological changes in PMC induced by C. difficile toxin A. TEM and SEM were used to examine naive PMC treated with 1 µg of toxin A per ml for 4 h (Fig. 4). Naive cells showed a regular distribution of granules with well-dispersed chromatin in the nuclei. The plasma membrane was normal, and granule contents were clearly visible (Fig. 4A). However, PMC treated with toxin A (Fig. 4C) showed a decreased number of membrane microvilli, changes in electrodense granules in the cytoplasm, and pyknotic nuclei with condensation of nuclear chromatin, all features characteristic of apoptosis. Furthermore, PMC treated with toxin A and observed with SEM (Fig. 4D) showed morphological changes and evidence of enhanced granule release compared with untreated cells (Fig. 4B).
|
DNA fragmentation. DNA from PMC treated with 1 µg of toxin A per ml showed a characteristic ladder pattern after agarose electrophoresis (Fig. 5, lane C). DNA from sham-treated PMC (Fig. 5, lane B) did not show DNA fragmentation.
|
| |
DISCUSSION |
|---|
|
|
|---|
In experimental enterocolitis, toxin A causes inflammation and
necrosis of the intestinal wall (24, 35, 44). Both mast cells and other leukocytes have been implicated in the pathophysiology of toxin A-induced mucosal damage. To understand the mechanisms involved, several in vivo and in vitro approaches have been used. For
example, the in vitro interaction of toxin A with rat peritoneal macrophages induces release of interleukin-1
and TNF-
, which attract and activate neutrophils (40). Toxin A also causes
release of RMCPII when injected in ileal loops of rats (6).
This effect can be inhibited with a specific antagonist of substance P
(34), suggesting that toxin A activates mast cells via
substance P released from adjacent sensory neurons (30).
Thus, macrophages, other leukocytes, and mast cells may play a role in
the inflammation and necrosis associated with toxin A.
Although mast cells are an important source of several inflammatory
mediators and have been implicated in toxin A-induced enterocolitis, no
studies about the direct action of toxin A on isolated mast cells have
been published. Thus, our study showed that low doses of toxin A induce
the secretion of TNF-
from freshly isolated mast cells in vitro.
This is to our knowledge, the first direct report showing that a
bacterial enterotoxin causes release of TNF-
from mast cells. The
ability of toxin A to induce release of TNF-
is not limited to mast
cells, as both toxins A and B cause release of TNF-
by human
monocytes (15).
In contrast to macrophages, mast cells store TNF-
in granules and
can therefore release it immediately after toxin A activation and
participate in the early phase of the inflammatory reaction. TNF-
is
also known to cause necrosis of epithelial cells of the intestine, as
well as inhibition of gastric motility (42). Thus, all the
above effects suggest that mast cell-derived TNF-
may play a role in
the mucosal damage and fluid accumulation observed in C. difficile-associated colitis.
Although the in vitro ability of toxin A to activate inflammatory cells such as neutrophils, macrophages, and mast cells (this study) has been demonstrated, the in vivo access of the toxin to these cells is in dispute because of the large size of the toxin. However, toxin A can cause detachment and apoptosis of enterocytes (27). In this disrupted epithelium, toxin A might diffuse and interact with inflammatory cells in the lamina propria, including mast cells.
In earlier reports, there is strong evidence that histamine is involved in the C. difficile toxin A experimental colitis in rats (25, 35). However, our results in vitro indicate that toxin A was not able to directly induce the secretion of histamine or NO from mast cells. This contrasts to the in vivo degranulation observed after injection of toxin A in intestinal loops (25), suggesting that histamine is released in vivo due to indirect activation of mast cells, such as with substance P released by enteric nerves (6, 30, 34).
Our results further document that in mast cells, the mechanisms for
TNF-
release are different from those involved in the release of
histamine. Furthermore, we found that toxin A inhibited antigen-dependent and -independent release of histamine by mast cells.
To release histamine, vesicles must move and fuse with the cell
membrane, a process that requires the participation of the
cytoskeleton. We found that in mast cells, like in other cell types,
toxin A disrupts the actin microfilaments; this alteration may reduce
the capacity of mast cells to release histamine contained in granules.
It was recently reported that C. difficile toxins A and B
alter cytoskeleton by monoglycosylation of GTP-binding proteins Rho and
Rac (17, 22, 23). These proteins have been shown to regulate
the role of the cytoskeleton during secretion of inflammatory mediators
in mast cells (33, 37, 38). However, the concentration of
toxin used to alter the PMC cytoskeleton was high, and it is probably
not achieved in vivo. Once again, degranulation of mast cells may occur
in vivo by activation of neuronal circuits.
NO is also an effector molecule produced by mast cells that could be
involved in the pathophysiology of enterocolitis (41). Interestingly, NO is able to potentiate mast cell cytotoxicity mediated
by TNF-
(5). However, toxin A did not stimulate NO synthesis by mast cells at any of the concentrations of toxin used.
Thus, direct interaction of toxin A with mast cells in vitro may
not induce NO production, although this does not preclude synthesis of
NO by mast cells or other cells induced by indirect mechanisms
such as neuropeptides. Recently, Qiu et al. (39) demonstrated that NO inhibits the enterotoxicity of toxin A on rat
small intestine; if NO acts as a mechanism of defense, this might come
from cells other than mast cells.
We found that prolonged exposure to toxin A caused apoptosis of PMC. This is the first report on induction of apoptosis in mast cells caused by a bacterial toxin. The induction of apoptosis by bacterial products has been documented in other cell types (8, 21, 32). In fact, toxin A caused apoptosis in human intestinal epithelial cells (27). The ability of toxin A to cause apoptosis raises the interesting possibility that Rho and Rac proteins may be involved in the mechanisms regulating program cell death. We are currently studying the mechanisms involved in toxin A-induced apoptosis in mast cells.
During the acute phase of inflammation and necrosis in the intestinal wall caused by C. difficile toxins, mast cells are active and releasing mediators such as RMCPII, platelet-activating factor, and leukotriene B4 (6, 26, 35). This finding suggests that toxin A-induced apoptosis may not occur at this stage. However, it could be that in severe cases of pseudomembranous colitis, mast cells in the lamina propria may be exposed to toxin A at doses or times that induce apoptosis; macrophages, monocytes, and neutrophils may also be affected (14, 15, 40). This would impair the ability of these cells to counteract infection and may explain in part why severe cases are so refractory to treatment and prone to recrudescence.
Our results suggest that mast cells may participate in the initial
inflammatory reaction by releasing TNF-
in response to toxin A. In
contrast, histamine and NO may not participate when toxin A acts
directly on mast cells. The disruption of the cytoskeleton caused by
the toxin A may alter the ability of mast cells to secrete histamine
and NO after antigen-dependent or -independent activation. In
opposition to the necrotic action of toxin A in other cell types, it
induces apoptosis in mast cells. Prolonged exposure to toxin A
decreases function and viability of intestinal inflammatory cells,
hindering their ability to counteract infection; this would probably
favor severe and long-lasting cases of pseudomembranous colitis.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by research grants 2095-M9303 and F564-M9312 from El Consejo Nacional de Ciencia y Tecnología (National Council of Science and Technology), Mexico, and by the Medical Research Council and Alberta Heritage Foundation for Medical Research, Canada. Gloria M. Calderón was supported by a doctoral scholarship from Dirección General de Asuntos del Personal Académico, UNAM, Mexico.
We thank Mauricio Sarrazola for assistance with statistical analysis.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Hospital de Pediatría, CMN Siglo XXI, Av. Cuauhtémoc 330 Col Doctores, México 06725, D.F., Mexico. Phone: (525) 627-69-40. Fax: (525) 627-69-49. E-mail: enciso{at}buzón.main.conacyt.mx.
Editor: J. T. Barbieri
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bartlett, J. G. 1994. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin. Infect. Dis. 18(Suppl. 4):S265-S272. |
| 2. | Befus, A. D., F. L. Pearce, J. Gauldie, P. Horsewood, and J. Bienenstock. 1982. Mucosal mast cells. I. Isolation and functional characteristics of rat intestinal mast cells. J. Immunol. 128:2475-2480[Abstract]. |
| 3. | Benyon, R. C., J. A. Enciso, and A. D. Befus. 1993. Analysis of human skin mast cell proteins by two-dimensional gel electrophoresis: identification of tryptase as a siaylated glycoprotein. J. Immunol. 151:2699-2706[Abstract]. |
| 4. |
Bissonnette, E. Y.,
J. A. Enciso, and A. D. Befus.
1997.
TGF- 1 inhibits the release of histamine and tumor necrosis factor- from mast cells through an autocrine pathway.
Am. J. Respir. Cell. Mol. Biol.
16:275-282[Abstract].
|
| 5. | Bissonnette, E. Y., C. M. Hogaboam, J. L. Wallace, and A. D. Befus. 1991. Potentiation of tumor necrosis factor-alpha-mediated cytotoxicity of mast cells by their production of nitric oxide. J. Immunol. 147:3060-3065[Abstract]. |
| 6. | Castagliuolo, I., J. T. LaMont, R. Letourneaur, C. Kelly, J. C. O'Keane, A. Jaffer, T. C. Theoharides, and C. Pothoulakis. 1994. Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology 107:657-665[Medline]. |
| 7. | Castex, N., J. Fioramonti, M. J. Fargeas, J. More, and L. Bueno. 1994. Role of 5-HT3 receptors and afferent fibers in the effects of mast cell degranulation on colonic motility in rats. Gastroenterology 107:976-984[Medline]. |
| 8. | Chen, Y., and A. Zychlinsky. 1994. Apoptosis induced by bacterial pathogens. Microb. Pathog. 17:203-212[Medline]. |
| 9. |
Däubener, W.,
E. Leiser,
C. von Eichel-Streiber, and U. Hadding.
1988.
Clostridium difficile toxin A and B inhibit human immune response in vitro.
Infect. Immun.
56:1107-1112 |
| 10. | Diaz-Barriga, F., L. Carrizales, L. Yañez, J. M. Hernandez, C. Dominguez-Robles, E. Palmer, and J. L. Saborio. 1989. Interaction of cadmiun with actin microfilaments in vitro. Toxic in vitro 3:277-284. |
| 11. | Echtenacher, B., D. N. Mannel, and L. Hultner. 1996. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75-77[Medline]. |
| 12. |
Eliakim, R.,
F. Karmeli,
E. Okon, and D. Rachmilewitz.
1992.
Ketotifen effectively prevents mucosal damage in experimental colitis.
Gut
33:1498-1503 |
| 13. | Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 95:99-105[Medline]. |
| 14. | Fiorentini, C., and M. Thelestam. 1991. Clostridium difficile toxin A and its effects on cells. Toxicon 29:543-567[Medline]. |
| 15. |
Flegel, W. A.,
F. Müller,
W. Däubener,
H. Fisher,
U. Hadding, and H. Northoff.
1991.
Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B.
Infect. Immun.
59:3659-3666 |
| 16. |
Galli, S. J.
1993.
New concepts about the mast cell.
N. Engl. J. Med.
328:257-265 |
| 17. | Giry, M., M. Popoff, C. von Eichel-Streiber, and P. Boquet. 1995. Transient expression of RhoA, -B, and -C GTPases in HeLa cells potentiates resistance to Clostridium difficile toxins A and B but not to Clostridium sordelii lethal toxin. Infect. Immun. 63:4063-4071[Abstract]. |
| 18. | Gonzalez-Robles, A., A. Lázaro-Haller, M. Espinoza-Cantellano, F. Anaya-Velazquez, and A. Martínez-Palomo. 1995. Trichomonas vaginalis: ultrastructural bases of the cytopathic effect. J. Eucaryotic Microbiol. 42:641-651. |
| 19. |
Goyal, R., and I. Hirano.
1996.
The enteric nervous system.
N. Engl. J. Med.
334:1106-1115 |
| 20. | Green, L. C., D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum. 1982. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal. Biochem. 126:131-138[Medline]. |
| 21. | Inward, C. D., J. Williams, I. Chant, J. Crocker, D. V. Milford, P. E. Rose, and M. Taylor. 1995. Verocytotoxin-1 induces apoptosis in Vero cells. J. Infect. 30:213-218[Medline]. |
| 22. | Just, I., J. Selzer, C. von Eichel-Streiber, and K. Aktories. 1995. The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile. J. Clin. Invest. 95:1026-1031. |
| 23. |
Just, I.,
M. Wilm,
J. Selzer,
G. Rex,
C. von Eichel-Streiber,
M. Mann, and K. Aktories.
1995.
The enterotoxin from Clostridium difficile (tox A) monoglucosylates the rho proteins.
J. Biol. Chem.
270:13932-13936 |
| 24. | Kelly, C., S. Becker, J. K. Linevsky, M. A. Joshi, J. C. O'Keane, B. F. Dickey, J. T. LaMont, and C. Pothoulakis. 1994. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J. Clin. Invest. 93:1257-1265. |
| 25. | Kurose, I., C. Pothoulakis, J. T. LaMont, D. C. Anderson, J. C. Paulson, M. Miyasaka, R. Wolf, and D. N. Granger. 1994. Clostridium difficile toxin A-induced microvascular dysfunction. Role of histamine. J. Clin. Invest. 94:1919-1926. |
| 26. | Lauritsen, K., L. Laursen, K. Bukhave, and J. Rask-Madsen. 1988. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis and Clostridium difficile colitis. Gastroenterology 95:11-17[Medline]. |
| 27. |
Mahida, Y. R.,
S. Makh,
S. Hyde,
T. Gray, and S. P. Borriello.
1996.
Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment.
Gut
38:337-347 |
| 28. | Malaviya, R., T. Ikeda, E. Ross, and S. N. Abraham. 1996. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 381:77-79[Medline]. |
| 29. | Mantyh, C. R., J. E. Maggio, P. Mantyh, S. Vigna, and T. N. Pappas. 1996. Increased substance P receptor expression by blood vessels and lymphoid aggregates in Clostridium difficile-induced pseudomembranous colitis. Digest. Dis. Sci. 41:614-620. |
| 30. | Mantyh, C. R., T. N. Pappas, J. A. Lapp, M. K. Washington, L. M. Neville, J. R. Ghilardi, S. D. Rogers, P. W. Mantyh, and S. R. Vigna. 1996. Substance P activation of enteric neurons in response to intraluminal Clostridium difficile toxin A in the rat ileum. Gastroenterology 111:1272-1280[Medline]. |
| 31. | Miller, P. D., C. Pothoulakis, T. R. Baeker, J. T. LaMont, and T. L. Rothstein. 1990. Macrophage-dependent stimulation of T cell-depleted spleen cells by Clostridium difficile toxin A and calcium ionophore. Cell. Immunol. 126:155-163[Medline]. |
| 32. | Morimoto, H., and J. Bonavida. 1992. Diphteria toxin and Pseudomonas toxin-mediated apoptosis. J. Immunol. 149:2089-2094[Abstract]. |
| 33. | Norman, J. C., L. S. Price, A. J. Ridley, and A. Koffer. 1996. The small GTP-binding proteins, rac and rho, regulate cytoskeletal organization and exocytosis in mast cells by parallel pathways. Mol. Biol. Cell 7:1429-1442[Abstract]. |
| 34. |
Pothoulakis, C.,
I. Castagliuolo,
J. T. LaMont,
A. Jaffer,
J. C. O'Keane,
R. M. Snider, and S. E. Leeman.
1994.
CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin.
Proc. Natl. Acad. Sci. USA
91:947-951 |
| 35. | Pothoulakis, C., F. Karmeli, C. P. Kelly, R. Eliakim, M. A. Joshi, J. C. O'Keane, I. Castagliuolo, J. T. LaMont, and D. Rachmilewitz. 1993. Ketotifen inhibits Clostridium difficile toxin A-induced enteritis in rat ileum. Gastroenterology 105:701-707[Medline]. |
| 36. | Pothoulakis, C., R. Sullivan, D. Melnick, G. Triadafilopoulos, A. S. Gadenne, T. Meshulam, and J. T. LaMont. 1988. Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J. Clin. Invest. 81:1741-1745. |
| 37. |
Prepens, U.,
I. Just,
C. von Eichel-Streiber, and K. Aktories.
1995.
Inhibition of Fc RI mediated activation of rat basophilic leukemia cells by Clostridium difficile toxin B (monoglucosyltransferase).
J. Biol. Chem.
271:7324-7329 |
| 38. | Price, L. S., J. Norman, A. J. Ridley, and A. Koffer. 1995. The small GTPases rac and rho as regulators of secretion in mast cells. Curr. Biol. 5:68-73[Medline]. |
| 39. | Qiu, B., C. Pothoulakis, I. Castagliulo, Z. Nikulasson, and J. T. LaMont. 1996. Nitric oxide inhibits rat intestinal secretion by Clostridium difficile toxin A but not Vibrio cholerae enterotoxin. Gastroenterology 111:409-418[Medline]. |
| 40. |
Rocha, M. F. G.,
M. E. T. Maia,
L. R. P. S. Bezerra,
D. M. Lyerly,
R. L. Guerrant,
R. A. Ribeiro, and A. M. Lima.
1997.
Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1 , tumor necrosis factor alpha, and leukotrienes.
Infect. Immun.
65:2740-2746[Abstract].
|
| 41. | Salvemini, D., E. Masini, A. Pistelli, P. F. Mannaioni, and J. Vane. 1991. Nitric oxide: a regulatory mediator of mast cell reactivity. J. Cardiovasc. Pharmacol. 17:S258-S265. |
| 42. | Sartor, R. B. 1994. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 106:533-541[Medline]. |
| 43. |
Shore, P. A.,
A. Burkhalter, and V. H. Cohn.
1959.
A method for the fluorometric assay of histamine in tissues.
J. Pharmacol. Exp. Ther.
127:182-186 |
| 44. |
Torres, J.,
E. Jennische,
S. Lange, and I. Lonnroth.
1990.
Enterotoxins from Clostridium difficile; diarrhoeogenic potency and morphological effects in the rat intestine.
Gut
31:781-785 |
| 45. | Torres, J. F., and I. Lonnroth. 1988. Comparison of methods for the production and purification of toxin A from Clostridium difficile. FEMS Microbiol. Lett. 52:41-46. |
| 46. | Torres, J. F., and I. Lonnroth. 1989. Production, purification and characterization of Clostridium difficile toxic proteins different from toxin A and from toxin B. Biochim. Biophys. Acta 998:151-157[Medline]. |
| 47. | White, J. R., and F. L. Pearce. 1982. Characteristics of histamine secretion from rat peritoneal mast cells sensitized to the nematode Nippostrongylus brasiliensis. Immunology 46:353-359[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|